B. Riley raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $460 from $422 and keeps a Buy rating on the shares. The company reported Q1 results, pointing to strong Rezdiffra U.S. sales trends, the analyst tells investors in a research note. The firm would buy the stock on any “sell-the-news” weakness.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $420 from $394 at Canaccord
- Madrigal Pharmaceuticals Reports Strong Q1 2025 Results
- Madrigal’s Earnings Call: Rezdiffra’s Success and Future Plans
- Madrigal Pharmaceuticals: Strong Financial Performance and Strategic Positioning Justify Buy Rating
- Madrigal Pharmaceuticals reports Q1 EPS ($3.32), consensus ($3.79)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue